Grants for Public Housing Authorities

This grant provides access to valuable biological samples and data for researchers studying common and serious health conditions, such as diabetes and kidney diseases, to support innovative research and development of new treatments.

The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s).Funding Opportunity Description Introduction The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), is transforming the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. This funding opportunity announcement (FOA) aims to promote innovative research to increase knowledge of understudied proteins associated with rare diseases. The submission of small research grant (R03) applications is encouraged from institutions and organizations proposing projects leading to a better understanding of eligible proteins listed below. Small research (R03) grants provide flexibility for initiating discrete, well-defined projects that realistically can be completed in one year and require only limited levels of funding. This program supports different types of projects including, but not limited to, the following: Pilot or feasibility studies; Small, self-contained research projects; Development of research methodology; and/or Development of assays to support compound screening projects; Development of human cell or animal based models. These awards will support generation of preliminary data and tools around eligible understudied protein(s) with the intent of elucidating the function of these proteins in the context of rare disease and obtaining sufficient preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. These grants are non-renewable. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Background The human genome has revealed a great deal about the human proteome, though significant portions of the genome remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be studied in the Druggable Proteome (DP), which can be defined as the fraction of proteins which have the ability to bind drug-like molecules. The term "drug-like" refers to the physical, biochemical, and pharmacological attributes of small molecule compounds that are generally recognized to be required for efficacious clinical drugs in humans. While the number of proteins in the DP is upwards of 4,500, the existing clinical pharmacopeia is represented by only a few hundred targets, leaving a huge swath of druggable biology unexploited. The expanded exploration of the relationship between the protein and the rare disease phenotype, or the development of a useful tool or reagent can accelerate research into a previously understudied protein. Many interesting and critical biological processes and potential therapeutic avenues remain unexplored because an initial catalyzing event (e.g., association with a biologic process or phenotype, creation of tools or reagents for the protein, etc.) has not yet occurred. The purpose of this FOA is to spark such catalyzing events through the support of small R03 awards to identify novel drug targets for the treatment of human disease, specifically rare disease Objectives and Scope The goal of this specific solicitation is to provide a needed opportunity for the collection of preliminary data around the role of understudied proteins associated with rare diseases. This FOA will provide funding to support research that will characterize new targets for treatment of human disease among the understudied proteins of the Druggable Proteome. These projects should be carried out in a short period of time with limited resources as defined by the funding mechanism. It has been recognized through workshops and publications that understudied proteins become illuminated when (1) there are tools to study the protein (e.g., tools that modulate protein activity) and/or (2) there is biochemical, cellular, or animal model evidence of disease/physiological relevance. This FOA was developed to address the need for expanded research and validation experiments on eligible understudied protein(s), with the intent of producing preliminary data to address the lack of biochemical, cellular, or animal model data associated with many understudied proteins. It is expected that the award will be used to obtain preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. The NIH supports research on a broad range of diseases that are defined as rare; that is diseases affecting fewer than 200,000 individuals in the United States (per the Rare Disease Act of 2002). Collectively, there are an estimated 7,000 rare diseases, which affect approximately 25-30 million people in the United States. Most are serious or life-threatening, with a disproportionate number of rare diseases affecting children. At this time, effective treatments are available for fewer than 5%. The IDG Program has linked over 6,000 proteins to rare diseases, with over 80% of these proteins considered extremely understudied. For the purposes of this FOA, eligible proteins are those that have an association with rare disease through data mining of the encyclopedia of rare disease annotations for precision medicine (eRAM) and Orphanet, are considered understudied (those proteins that lack small molecule binders and/or have limited biological characterization) and are within a protein family that is traditionally considered druggable.

This grant provides funding to researchers for planning clinical trials that improve cancer prevention, treatment, and care, addressing gaps in knowledge and feasibility to enhance study design and outcomes.

This grant provides funding to researchers planning clinical trials focused on cancer prevention and control, helping them address challenges and improve the design and feasibility of their studies.

This funding opportunity supports innovative research to develop combination cancer therapies that integrate radiation treatment with targeted molecular agents, aimed at improving treatment effectiveness while reducing side effects.

This funding opportunity supports research projects that explore innovative combinations of radiation therapy and other treatments to improve cancer care, inviting applications from a diverse range of organizations, including universities, nonprofits, and for-profit entities.

This funding opportunity supports U.S.-based researchers and organizations in developing innovative cancer communication strategies using advanced technologies to improve cancer prevention, control, and patient care.

This grant provides funding for researchers to develop innovative methods for improving cancer communication and prevention strategies in today's digital landscape, focusing on the impact of online information and health disparities.

This funding opportunity provides financial support for new and at-risk researchers from diverse backgrounds to conduct independent scientific studies, particularly in areas addressing health disparities and underrepresented populations.

This grant provides preclinical support services to researchers developing innovative HIV therapies and addressing related health issues, enabling them to advance their drug development efforts.

This funding opportunity supports interdisciplinary research teams focused on understanding the brain mechanisms behind mental disorders and translating these findings into clinical applications, particularly for severe mental illnesses and developmental psychopathology in children and adolescents.

This funding opportunity supports innovative research using invasive technologies to study the human brain, encouraging collaboration among diverse experts to advance our understanding of neuroscience.

This funding opportunity supports researchers in the life sciences to pursue innovative and ambitious projects, providing them with stable financial backing and the flexibility to explore new research directions.

This FOA will support integrated, interdisciplinary research teams that focus on examining dynamic circuit functions related to behavior, using advanced and innovative technologies. The FOA will support programs with a necessarily-synergistic, team science approach. Awards will be made for 5 years, with a possibility of one competing renewal. Applications should incorporate overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. Applications should incorporate theory-/model-driven experimental design and should offer predictive models as deliverables. Applications should seek to understand circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Applications are expected to employ approaches guided by specified theoretical constructs, and are encouraged to employ quantitative, mechanistic models where appropriate. Applications will be required to manage their data and analysis methods in a framework that will be developed and used in the proposed U19 project and exchanged with other BRAIN U19 awardees for further refinement and development. Model systems, including the possibility of multiple species ranging from invertebrates to humans, can be employed and should be appropriately justified. Programs should employ multi-component teams of research expertise including neurobiologists, statisticians, physicists, mathematicians, engineers, computer scientists, and data scientists, as appropriate - that seek to cross boundaries of interdisciplinary collaboration. Applicants proposing to include human subjects with invasive neural recording must apply to the companion FOA, RFA-NS-XX-XXX.

This grant provides funding for innovative research aimed at understanding the biological and immunological factors that contribute to the increased susceptibility of transgender individuals to HIV and other sexually transmitted infections.

This grant provides funding for researchers to develop and implement strategies that improve HIV prevention and care for individuals who use stimulants, particularly those who also use opioids or other substances, while promoting diversity and community engagement in the research process.

Reissue PAR-19-220.

This funding opportunity provides financial support to current AHRQ grant holders to recruit and retain diverse students and early-career researchers in health services research, while also accommodating PIs with disabilities.

This funding opportunity provides financial support for research projects that aim to improve the adoption and sustainability of effective health interventions, particularly in underrepresented communities, by addressing barriers and promoting equitable health outcomes.

This funding opportunity supports research projects that aim to improve the adoption and sustainability of effective health interventions, particularly in underserved communities, while also addressing the reduction of ineffective practices.